Cargando…
Sp1 and COX2 expression is positively correlated with a poor prognosis in pancreatic ductal adenocarcinoma
Previous studies showed that celecoxib, a cyclooxygenase-2 (COX2) inhibitor, can inhibit angiogenesis and metastasis of pancreatic ductal adenocarcinoma (PDAC) via the suppression of specificity protein 1 (Sp1). In this study, we investigated the prognostic value of Sp1 and COX2 in 88 PDAC patients....
Autores principales: | Hang, Junjie, Hu, Hai, Huang, Junjie, Han, Ting, Zhuo, Meng, Zhou, Yangyang, Wang, Lei, Wang, Yi, Jiao, Feng, Wang, Liwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053721/ https://www.ncbi.nlm.nih.gov/pubmed/27057636 http://dx.doi.org/10.18632/oncotarget.8593 |
Ejemplares similares
-
Simultaneous high expression of PLD1 and Sp1 predicts a poor prognosis for pancreatic ductal adenocarcinoma patients
por: Hu, Jiong, et al.
Publicado: (2016) -
EGFR, but not COX-2, protein in resected pancreatic ductal adenocarcinoma is associated with poor survival
por: Fagman, Johan Bourghardt, et al.
Publicado: (2019) -
A novel feedback loop between high MALAT-1 and low miR-200c-3p promotes cell migration and invasion in pancreatic ductal adenocarcinoma and is predictive of poor prognosis
por: Zhuo, Meng, et al.
Publicado: (2018) -
Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma
por: Yang, Jian-Yu, et al.
Publicado: (2015) -
Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma
por: Saukkonen, Kapo, et al.
Publicado: (2015)